In the last trading session, 6.92 million shares of the Petros Pharmaceuticals Inc (NASDAQ:PTPI) were traded, and its beta was 2.19. Most recently the company’s share price was $0.21, and it changed around -$0.04 or -15.26% from the last close, which brings the market valuation of the company to $0.45M. PTPI currently trades at a discount to its 52-week high of $19.16, offering almost -9023.81% off that amount. The share price’s 52-week low was $0.23, which indicates that the current value has fallen by an impressive -9.52% since then.
Petros Pharmaceuticals Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended PTPI as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight.
Petros Pharmaceuticals Inc (NASDAQ:PTPI) trade information
Instantly PTPI has showed a red trend with a performance of -15.26% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.0000 on recent trading dayincreased the stock’s daily price by 79.0%. The company’s shares are currently down -97.86% year-to-date, but still down -85.42% over the last five days. On the other hand, Petros Pharmaceuticals Inc (NASDAQ:PTPI) is -87.68% down in the 30-day period.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 55.46%.
PTPI Dividends
Petros Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in June.
Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund were the top two Mutual Funds as of Feb 28, 2025 . The former held 1.39 shares worth $292.0, making up 0.06% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund held roughly 1.27 shares worth around $268.0, which represents about 0.06% of the total shares outstanding.
